Comparing commercial pharmacogenetic testing results and recommendations for antidepressants with established CPIC guidelines.

ABSTRACT:

Introduction

Increasingly, pharmacogenetic testing helps providers with medication selection based upon patient-specific DNA results. While several government-funded organizations work towards consensus and standardization for testing and interpretation, compliance to these best practices remains inconsistent. Pharmacogenetic testing companies often develop proprietary practices for interpreting and reporting, which can lead to incongruency of reported results among companies and potential discrepancies in interpretation.

Methods

To identify the differences of commercial pharmacogenetic testing vendors' interpretation of genotype-to-phenotype translations and medication recommendations from the Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines, a retrospec

SUBMITTER: Nguyen TT 

PROVIDER: S-EPMC11626124 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature